Acumen pharmaceuticals completes enrollment in phase 1 trial of acu193, first monoclonal antibody developed to selectively target toxic aΒ oligomers in patients with early alzheimer's disease

Topline results including safety and proof-of-mechanism data expected in third quarter of 2023 topline results including safety and proof-of-mechanism data expected in third quarter of 2023
ABOS Ratings Summary
ABOS Quant Ranking